Cure Ventures
Overview
Cure Ventures is a life sciences venture capital firm focusing on de novo company formation around groundbreaking curative technologies. The firm focuses on early-stage investments in life science and biotechnology, primarily focused in new therapeutics. Cure's unique approach also embraces genetic validation as part of an iterative process to guide a drug through development, increasing the probability of success and mitigating the cost of failure. Embedded Cure operators work alongside portfolio company founders to drive day-to-day decision making.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Tortugas Neuroscience | Apr 2026 | Seed | Lead |
| Tasca Therapeutics | Sep 2025 | Series A | Lead |
| Tasca Therapeutics | Dec 2024 | Series A | Lead |
| Clasp Therapeutics | Mar 2024 | Series A | Co-investor |
| Kenai Therapeutics | Feb 2024 | Series A | Lead |
Key People
Richard Lim
Managing Partner And Co-Founder
Albert J Robichaud
Partner
Annie Mitsak
Partner
Jeffrey Jonas
Partner
Jeno Gyuris
Partner
Kenzie MacIsaac
Partner
May Han
Partner
milenko cicmil
Partner
Bill Amsbaugh
Chief Technology Officer, Partner
Drew King
Partner And Chief Financial Officer
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.